We discovered it, we named it, we are drugging it: our oxMIF-targeting pipeline

OncoOne is generating novel biotherapeutics targeting oxMIF for the treatment of solid tumors and chronic inflammatory diseases. In addition, OncoOne launched its PreTarg-it® platform to broaden its portfolio to other targets and cancer indications.